ArticleTherapeutic advances in neurological disorders2015
The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: a systematic review and meta-analysis.
Article in Therapeutic advances in neurological disorders, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Whole brain volume loss is associated with a short-term disability progression in relapse-activity free multiple sclerosis.Journal of neurology · 2025Observational
- Treatment of relapsing multiple sclerosis - recommendations of the Croatian Neurological Society.Croatian medical journal · 2022Review
- Perivascular space is associated with brain atrophy in patients with multiple sclerosis.Quantitative imaging in medicine and surgery · 2022Article
- Cognitive impairment and depression in patients with relapsing-remitting multiple sclerosis depending on age and neuroimaging findings.The Egyptian journal of neurology, psychiatry and neurosurgery · 2021Article
- Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis ofFrontiers in neurology · 2021Article
- Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).Therapeutic advances in neurological disorders · 2021Review
- Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study.NeuroImage. Clinical · 2021Article
- Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options.Auto- immunity highlights · 2019Review
- Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in.Translational neurodegeneration · 2019Review
- Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine.AJNR. American journal of neuroradiology · 2018Article
- Future Brain and Spinal Cord Volumetric Imaging in the Clinic for Monitoring Treatment Response in MS.Current treatment options in neurology · 2018Review
- Gene variants of adhesion molecules act as modifiers of disease severity in MS.Neurology(R) neuroimmunology & neuroinflammation · 2017Article
- Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study.Neurology · 2017Article
- Article
- Brain Atrophy in Dogs With Meningoencephalitis of Unknown Origin.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesBrain atrophy is associated with cognitive deficits in patients with clinically isolated syndrome (CIS) and can predict conversion to clinical definite multiple sclerosis. The aim of the present meta-analysis was to evaluate the effect of disease-modifying drugs (DMDs) on brain atrophy in patients with CIS.
methodsEligible placebo-control randomized clinical trials of patients with CIS that had reported changes in brain volume during the study period were identified by searching the MEDLINE, SCOPUS, and Cochrane Central Register of Controlled Trials (CENTRAL) databases. This meta-analysis adopted the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for systematic reviews and meta-analyses.
resultsThree eligible studies were identified, comprising 1362 patients. The mean percentage change in brain volume was found to be significantly lower in DMD-treated patients versus placebo-treated subgroups (standardized mean difference [SMD]: = -0.13, 95% confidence interval [CI]: -0.25, 0.01; p = 0.04). In the subgroup analysis of the two studies that provided data on brain-volume changes for the first (0-12 months) and second (13-24 months) year of treatment, DMD attenuated brain-volume loss in comparison with placebo during the second year (SMD = -0.25; 95% CI: -0.43, -0.07; p < 0.001), but not during the first year of treatment (SMD = -0.01; 95% CI: -0.27, 0.24; p = 0.93). No evidence of heterogeneity was found between estimates, while funnel-plot inspection revealed no evidence of publication bias.
conclusionsDMDs appear to attenuate brain atrophy over time in patients with CIS. The effect of DMDs on brain-volume loss is evident after the first year of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.